Plant Name: Dasycladus vermicularis
Taxonomic Information:
Plant ID: NPO15639
Plant Latin Name: Dasycladus vermicularis
Taxonomy Genus: Dasycladus
Taxonomy Family: Dasycladaceae
Plant External Links:
NCBI TaxonomyDB:
1818018
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ALPL; HSD17B10; | |
| GAA; | |
| CA2; CA1; CA7; CA4; CA6; CA12; CA9; CA14; | |
| NFKB1; TP53; | |
| MAPT; PFKFB3; RAB9A; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | Q16875 | CHEMBL2331053 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.895E-08 | 4.126E-05 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.638E-07 | 1.288E-03 | CA1, CA12, CA2, CA4, CA6, CA7, CA9, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.054E-06 | 4.750E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.565E-06 | 7.128E-03 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.682E-21 | 3.664E-17 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.560E-17 | 4.965E-13 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.199E-15 | 1.742E-11 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.310E-05 | 1.426E-02 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.524E-05 | 1.580E-02 | CA1, CA2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.561E-05 | 3.310E-02 | CYP2C19, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.807E-21 | 4.518E-19 | CA12, CA1, CA2, CA4, CA7, CA6, CA9, CA14 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.296E-05 | 2.019E-03 | CYP2C9, CYP2D6, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.818E-04 | 5.578E-03 | CYP2C9, CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.221E-04 | 5.946E-03 | RAB9A, TP53, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.019E-03 | 1.368E-02 | CYP2C9, GAA, ALPL, CYP2C19, HSD17B10, XDH |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.374E-04 | 5.578E-03 | CA2, CA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.795E-04 | 5.946E-03 | CYP2C9, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.989E-03 | 1.870E-02 | MAPT, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.733E-03 | 1.870E-02 | CYP2C9, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.961E-03 | 1.870E-02 | TP53, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PFKFB3; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
